Settling an over three old patent infringement dispute, Indian pharmaceutical major,
While the settlement terms, including exact dates and amount that can be manufactured/sold, has been kept confidential, what has been disclosed is that Celgene will grant Sun Pharma a license to manufacture and sell (subject to USFDA approval) generic lenalidomide capsules in the US (a) limited quantity sometime after
Lenalidomide (brand name Revlimid by Celgene) is a thalidomide derivative used to treat multiple myeloma and anemia in low to intermediate-risk myelodysplastic syndrome. For Celgene/BMS Revlimid has turned out to be a blockbuster drug generating over
The patents involved in the infringement suit and settlement are:
-
S. Patents No. 7,977,357 titled Polymorphic forms of 3-(4-amino-1-oxo-1, 3 dihydro-isoindo1-2-yl)-piperidine-2,6-dione
- S. Patents No. 8,193,219 titled Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione, and
- S. Patents No. 8,431,598 titled Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
The above patents are anticipated to expire around
Previously, Celgene made similar settlements over patent litigations of Revlimid with Indian pharmaceutical companies —
Sun Pharma And Celegene Settle Patent Dispute Over Lenalidomide (Revlimid®)
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
Khurana And Khurana
Khurana and Khurana
E-13, UPSIDC, Site-IV, Behind-Grand Venice
201310
Tel: 1204296878
Fax: 1204516201
E-mail: tarun@khuranaandkhurana.com
URL: www.khuranaandkhurana.com
© Mondaq Ltd, 2021 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source